Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis
Abstract Objective Bisphosphonates and denosumab can increase bone mineral density (BMD) and are used to treat osteoporosis caused by aromatase inhibitors (AIs). However, few studies have been conducted on the effects of both on vertebral compression fractures (VCFs). This article aims to compare th...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2025-11-01
|
| Saila: | BMC Musculoskeletal Disorders |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12891-025-09280-w |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|